Association between use of specific drugs and antiretroviral adherence: Findings from MACH 14

AIDS and Behavior

Volumn 17, Issue 1, 2013, Pages 142-147

  Rosen, M I ^a,b   Black, A C ^a,b   Arnsten, J H ^c   Goggin, K ^d   Remien, R H ^e   Simoni, J M ^f   Golin, C E ^g   Bangsberg, D R ^h,i,j,k   Liu, H ^l  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h Mbarara University of Science and Technology   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Adherence; AIDS; Cannabis; HIV; Substance use

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADDICTION; ADULT; ALCOHOLISM; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PREVALENCE; PSYCHOLOGICAL ASPECT; SOCIOECONOMICS; STATISTICS; UNITED STATES;

ADULT; ALCOHOL-RELATED DISORDERS; ANTI-HIV AGENTS; DATA COLLECTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

MLCS; MLOWN;

EID: 84872680104     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-0124-7     Document Type: Article

References (36)

1. Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritt E. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. J Gen Intern Med. 2001;16(12):850-9.
2. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16(9):625-33.
3. Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493-9.
4. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944-50.
5. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr. 2004;35(1):46-51.
6. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968-77.
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
8. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(3):15.
9. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276(24):1955-6.
10. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939-41.
11. Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S118-22.
12. Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242-57.
13. Chander G, Himelhoch S, Moore RD, Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66(6):769-89.
14. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377-81.
15. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to Highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-5.
16. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185-94.
17. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18:19-25.
18. Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clin Trials. 2003;4(4):269-81.
19. Golin C, Liu H, Hays R, Miller L, Beck C, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17(10):756-65.
20. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16(16):2175-82.
21. Reinhard MJ, Hinkin CH, Barclay TR, Levine AJ, Marion S, Castellon SA, et al. Discrepancies between self-report and objective measures for stimulant drug use in HIV: cognitive, medication adherence and psychological correlates. Addict Behav. 2007;32(12):2727-36.
22. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180-202.
23. Liu H, Wilson IB, Goggin K, Reynolds NR, Simoni JM, Golin CE, et al. MACH14: a multi-site collaboration on ART adherence among 14 institutions (Under Review).
24. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19(11):1111-7.
25. Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;15(6):775-85.
26. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251-9.
27. Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98(3):269-79.
28. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect. 2003;79(1):59-61.
29. Tucker JS, Burnam MA, Sherbourne CD, Kung F-Y, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573-80.
30. Corless IB, Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, et al. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18(2):172-93.
31. De Jong BC, Prentiss D, McFarland W. MAchekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr. 2005;38(1):43-6.
32. Demas P, Schoenbaum EE, Wills TA, Doll LS, Klein RS. Stress, coping, and attitudes toward HIV treatment in injecting drug users: a qualitative study. AIDS Educ Prev. 1995;7(5):429-42.
33. Rosen MI, Rigsby MO, Dieckhaus KD, Cramer JA. Effects of illicit drug use on adherence to prescribed antiretroviral medication. Am J Addict. 2003;12(5):455-8.
34. Kosten TA, Rounsaville BJ. Sensitivity of psychiatric diagnosis based on the best estimate procedure. Am J Psychiatry. 1992;149(9):1225-7.
35. Braithwaite RS, Conigliaro J, McGinnis KA, Maisto SA, Bryant K, Justice AC. Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. Alcohol Clin Exp Res. 2008;32(9):1645-51.
36. Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45(10):1377-85.